NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

INTANGIBLE ASSETS (Tables)

6 Months Ended

Mar. 31, 2019

Intangible assets at March 31, 2019 and September 30, 2018:

	March 31, 2019			September 30, 2018
License Rights	$	17,712,991		$	17,712,991
Patent Costs		100,000			100,000
		17,812,991			17,812,991
Accumulated Amortization and impairment		(10,527,540	)		(10,201,073	)
Total Intangible Assets	$	7,285,451		$	7,611,918